Clinical Trial Update: Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating durvalumab + tremelimumab + enfortumab vedotin versus durvalumab + enfortumab vedotin in cisplatin-ineligible or cisplatin-refusing mus…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• Durvalumab (Imfinzi) (durvalumab)
• Enfortumab Vedotin (Padcev) (enfortumab vedotin)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: AstraZeneca | Conditions: Muscle Invasive Bladder Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING